HEAD & NECK CANCERS

Latest News

FDA Green Lights FTD of RRx-001 to Mitigate Severe Oral Mucositis in Head and Neck Cancers
FDA Green Lights FTD of RRx-001 to Mitigate Severe Oral Mucositis in Head and Neck Cancers

March 30th 2023

The FDA has granted a fast-track designation for RRx-001 and accepted the investigational new drug application for a phase 2b trial of severe oral mucositis in chemotherapy- and radiation-treated patients with head & neck cancer.

FDA Grants Priority Review to NDA of Avasopasem for RT-Induced Severe Oral Mucositis
FDA Grants Priority Review to NDA of Avasopasem for RT-Induced Severe Oral Mucositis

February 20th 2023

Precision Oncology Inches into Head and Neck Cancer Paradigm
Precision Oncology Inches into Head and Neck Cancer Paradigm

February 4th 2023

FDA Decision on Toripalimab for Advanced Nasopharyngeal Carcinoma Pending Due COVID-19 Travel Restrictions
FDA Decision on Toripalimab for Advanced Nasopharyngeal Carcinoma Pending Due COVID-19 Travel Restrictions

December 24th 2022

Evaluating the Incidence of HPV-Positive/-Negative, According to NCCN Guidelines
Evaluating the Incidence of HPV-Positive/-Negative, According to NCCN Guidelines

December 23rd 2022

More News